Pharmaceutical

Zenas raises $200m to advance autoimmune antibody therapy

Zenas signed a licencing deal for Asia-Pacific territories for the bispecific antibody, obexelimab, with Bristol Myers Squibb in September.

May 9, 2024 - 00:00
Zenas raises $200m to advance autoimmune antibody therapy
Zenas signed a licencing deal for Asia-Pacific territories for the bispecific antibody, obexelimab, with Bristol Myers Squibb in September.
Read the original article

Tags:

Previous Article

Biotechs must prioritise ethics to deter GenAI “bad actors”

Next Article

FDA fast track status granted to iECURE neonatal OTC deficiency treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Cataract drugs in development, 2023

Nov 30, 2023

Opinion: Remembering Betty Rollin, who told her breast surgeon that post-operative appearance mattered to her—and other women

Opinion: Remembering Betty Rollin, who told her breast ...

Dec 27, 2023

Developing high-potent APIs: The necessary steps to follow

Developing high-potent APIs: The necessary steps to follow

Aug 7, 2024